open access

Vol 67, No 5 (2009)
Other
Published online: 2009-05-20
Submitted: 2012-12-28
Get Citation

Original article
Intracoronary administration of stem cells in patients with acute myocardial infarction – angiographic follow-up

Jan Peruga, Michał Plewka, Jarosław Kasprzak, Tomasz Jeżewski, Agnieszka Wierzbowska, Tadeusz Robak, Maria Krzemińska Pakuła
Kardiol Pol 2009;67(5):477-484.

open access

Vol 67, No 5 (2009)
Other
Published online: 2009-05-20
Submitted: 2012-12-28

Abstract


Background: Even up-to-date reperfusion therapy using primary percutaneous intervention (PCI) in acute myocardial infarction does not result in improvement of the left ventricular (LV) function in all patients. Cellular myoblasty, a novel method using mononuclear bone marrow cells (BMC), can be applied in the infarcted myocardium area to stimulate regeneration and to limit the organ damage. However, the impact of intracoronary BMC administration on the effect of PCI is not clear.
Aim: To assess angiographic outcomes in patients with anterior myocardial infarction and LV dysfunction, undergoing intracoronary BMC administration after a successful primary PCI.
Methods: The study group consisted of 40 patients (mean age 56.2 years) with LV ejection fraction below 40%, in whom 20 ml of BMC were administered to the infarct-related artery (IRA) distally to the occlusion. The control group comprised 25 age- and sex-matched patients with similar values of LV ejection fraction undergoing bare metal stenting of IRA without BMC administration. Quantitative coronary angiography was performed 6 months later to assess IRA patency.
Results: The reference diameter of the stented artery decreased in the study group from 3.22 &#177; 0.28 mm to 3.16 &#177; 0.18 mm (p < 0.05) and in the control group from 3.22 &#177; 0.31 mm to 3.15 &#177; 0.28 mm (p < 0.082); also in the area of the implanted stent the diameter decreased from 3.57 &#177; 0.21 mm to 2.96 &#177; 0.79 mm in the study group vs. 3.48 &#177; 0.22 mm to 3.01 &#177; 0.35 mm in the control group. For lumen diameter measured 10 mm distally to the stent, the diameter loss was similar in both groups. In 6 patients from the BMC treated group and in 3 patients from the control group there was asymptomatic lumen reduction > 70% (NS).
Conclusion: The results of our study show that BMC administration into IRA is safe. The degree of lumen loss in the stent area was larger in the BMC group than in the control group. There was no significant difference in the lumen change distally to the stent; the artery diameter loss in both groups was similar, and the improvement in LV ejection fraction was greater in the BMC-treated group.

Abstract


Background: Even up-to-date reperfusion therapy using primary percutaneous intervention (PCI) in acute myocardial infarction does not result in improvement of the left ventricular (LV) function in all patients. Cellular myoblasty, a novel method using mononuclear bone marrow cells (BMC), can be applied in the infarcted myocardium area to stimulate regeneration and to limit the organ damage. However, the impact of intracoronary BMC administration on the effect of PCI is not clear.
Aim: To assess angiographic outcomes in patients with anterior myocardial infarction and LV dysfunction, undergoing intracoronary BMC administration after a successful primary PCI.
Methods: The study group consisted of 40 patients (mean age 56.2 years) with LV ejection fraction below 40%, in whom 20 ml of BMC were administered to the infarct-related artery (IRA) distally to the occlusion. The control group comprised 25 age- and sex-matched patients with similar values of LV ejection fraction undergoing bare metal stenting of IRA without BMC administration. Quantitative coronary angiography was performed 6 months later to assess IRA patency.
Results: The reference diameter of the stented artery decreased in the study group from 3.22 &#177; 0.28 mm to 3.16 &#177; 0.18 mm (p < 0.05) and in the control group from 3.22 &#177; 0.31 mm to 3.15 &#177; 0.28 mm (p < 0.082); also in the area of the implanted stent the diameter decreased from 3.57 &#177; 0.21 mm to 2.96 &#177; 0.79 mm in the study group vs. 3.48 &#177; 0.22 mm to 3.01 &#177; 0.35 mm in the control group. For lumen diameter measured 10 mm distally to the stent, the diameter loss was similar in both groups. In 6 patients from the BMC treated group and in 3 patients from the control group there was asymptomatic lumen reduction > 70% (NS).
Conclusion: The results of our study show that BMC administration into IRA is safe. The degree of lumen loss in the stent area was larger in the BMC group than in the control group. There was no significant difference in the lumen change distally to the stent; the artery diameter loss in both groups was similar, and the improvement in LV ejection fraction was greater in the BMC-treated group.
Get Citation

Keywords

myocardial infarction; stem-cell therapy; angiography

About this article
Title

Original article
Intracoronary administration of stem cells in patients with acute myocardial infarction – angiographic follow-up

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 67, No 5 (2009)

Pages

477-484

Published online

2009-05-20

Bibliographic record

Kardiol Pol 2009;67(5):477-484.

Keywords

myocardial infarction
stem-cell therapy
angiography

Authors

Jan Peruga
Michał Plewka
Jarosław Kasprzak
Tomasz Jeżewski
Agnieszka Wierzbowska
Tadeusz Robak
Maria Krzemińska Pakuła

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl